- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
DUSA Market Currents
more »
-
May 8 DUSA Pharmaceuticals (DUSA): Q1 EPS of $0.08 misses by $0.01. Revenue of $13.4M (+21.8% Y/Y) beats by $0.4M. (PR)
Comment![Earnings, Healthcare]
DUSA in Focus
more »
DUSA Related Articles
more »
DUSA News
more »
-
at MarketWatch.com (Mar 6, 2012)
-
at MarketWatch.com (May 5, 2011)
-
at MarketWatch.com (Mar 3, 2011)
DUSA Press Releases and Filings
more »
-
GlobeNewswire (May 8, 2012)
-
GlobeNewswire (May 1, 2012)
-
GlobeNewswire (Apr 24, 2012)
-
GlobeNewswire (Apr 10, 2012)
-
GlobeNewswire (Mar 23, 2012)
DUSA Latest Transcript
more »
Currently, there are no transcripts for DUSA.
DUSA Cramer
more »
Currently, there are no Cramer articles on DUSA.
DUSA Instablog posts
more »
DUSA vs. ETF Alternatives
Company Description
DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan®... More